Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
25.96 USD | +8.17% | +8.53% | +229.02% |
May. 31 | Jasper Therapeutics, Inc. to Present Data on Briquilimab in Mast Cell Driven Diseases at the EAACI Congress 2024 | CI |
May. 20 | Transcript : Jasper Therapeutics, Inc. - Special Call |
Business Summary
Number of employees: 45
Managers
Managers | Title | Age | Since |
---|---|---|---|
Ronald Martell
CEO | Chief Executive Officer | 62 | 22-03-14 |
Herbert Cross
DFI | Director of Finance/CFO | 52 | 23-09-21 |
Luca Di Noto
CTO | Chief Tech/Sci/R&D Officer | - | 19-12-31 |
Wendy Pang
CTO | Chief Tech/Sci/R&D Officer | - | 19-12-31 |
Edwin Tucker
CTO | Chief Tech/Sci/R&D Officer | 52 | 23-06-11 |
Jeet Mahal
COO | Chief Operating Officer | 52 | 19-11-30 |
Matthew Ford
HRO | Human Resources Officer | - | 23-04-12 |
David Hinds
PRN | Corporate Officer/Principal | - | 23-04-09 |
Patricia Carlos
LAW | General Counsel | - | 23-08-01 |
Arjun Agarwal
AUD | Comptroller/Controller/Auditor | - | 20-12-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Ronald Martell
CEO | Chief Executive Officer | 62 | 22-03-14 |
Thomas Wiggans
CHM | Chairman | 72 | Oct. 31 |
Kurt von Emster
BRD | Director/Board Member | 56 | 21-09-23 |
Scott Brun
BRD | Director/Board Member | 56 | 23-06-19 |
Vishal Kapoor
BRD | Director/Board Member | 48 | 23-02-15 |
Christian Nolet
BRD | Director/Board Member | 67 | 21-09-23 |
Anna Phil
BRD | Director/Board Member | 36 | 19-09-23 |
Judith Shizuru
FOU | Founder | 68 | 18-02-28 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 15,085,553 | 14,087,774 ( 93.39 %) | 0 | 93.39 % |
Company contact information
Jasper Therapeutics, Inc.
2200 Bridge Parkway Suite 102
94065, Redwood City
+
http://www.jaspertherapeutics.comSector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+229.02% | 392M | |
+40.73% | 739B | |
+31.70% | 598B | |
-6.30% | 353B | |
+15.15% | 318B | |
+4.05% | 285B | |
+14.47% | 240B | |
+9.19% | 210B | |
-5.32% | 206B | |
+6.17% | 164B |
- Stock Market
- Equities
- JSPR Stock
- Company Jasper Therapeutics, Inc.